Current Allergy and Asthma Reports最新文献

{"title":"Using the Electronic Health Record to Facilitate Drug Allergy Delabeling.","authors":"Matthew J Molloy, Adam P Yan, Averi E Wilson, Jonathan Beus, Lauren M Hess","doi":"10.1007/s11882-025-01229-2","DOIUrl":"https://doi.org/10.1007/s11882-025-01229-2","url":null,"abstract":"<p><strong>Purpose of review: </strong>There is a growing number of allergy delabeling programs across diverse clinical specialties and care settings. The electronic health record (EHR) can be leveraged to facilitate allergy delabeling. The purpose of this review is to describe EHR tools that have been used in allergy delabeling programs. We also provide recommendations for organizations considering EHR-based allergy delabeling workflows that incorporate clinical informatics best practices.</p><p><strong>Recent findings: </strong>Recent literature describes several EHR tools used in delabeling. These tools can be organized around the steps of the allergy delabeling workflow: 1. Identify eligible patients, 2. Risk stratify, 3. Evaluation and testing, 4. Documentation of outcome, 5. Delabeling, and 6. Allergy label reconciliation. Standardized EHR tools across the allergy delabeling workflow can lead to successful delabeling and support of diverse stakeholders. Partnering with EHR vendors presents an opportunity to make these tools readily available and improve allergy documentation.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":"25 1","pages":"49"},"PeriodicalIF":4.6,"publicationDate":"2025-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145369183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What is New in Contact Allergy To Cosmetics for Physicians, Cosmetologists, and Cosmetic Users?","authors":"Thanisorn Sukakul, Cecilia Svedman","doi":"10.1007/s11882-025-01226-5","DOIUrl":"https://doi.org/10.1007/s11882-025-01226-5","url":null,"abstract":"<p><strong>Purpose of review: </strong>This paper aims to evaluate the burden of contact allergy caused by cosmetic products, identifying the key allergens involved and examining recent regulatory and diagnostic developments. The review addresses which substances commonly induce allergic contact dermatitis and how current trends and emerging allergens impact clinical practice.</p><p><strong>Recent findings: </strong>Fragrances remain the most prevalent cosmetic allergens, with numerous compounds capable of triggering sensitization. Recent regulatory improvements in fragrance labeling are helping to reduce exposure to major allergens. Preservatives such as formaldehyde and isothiazolinones have historically caused widespread allergic reactions, but restrictions have lowered their incidence. Hair cosmetic allergens, especially para-phenylenediamine (PPD) and related chemicals, continue to cause significant allergic responses in consumers and professionals. Newly recognized allergens appear in sunscreens, skin lightening agents, and natural ingredients like propolis and carvone. The primary diagnostic methods include patch testing with baseline and specialized cosmetic allergen panels, photopatch testing for photoallergens, and repeated open application tests to support clinical evaluation. Contact allergy due to cosmetics is a growing dermatological issue, primarily driven by fragrances and hair dye allergens, with emerging allergens contributing to the evolving landscape. Continued vigilance in diagnosis, improved regulatory measures, and increased reporting are essential to reduce allergy rates and enhance patient care. This review underlines the need for ongoing research and prevention strategies targeting novel cosmetic allergens.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":"25 1","pages":"48"},"PeriodicalIF":4.6,"publicationDate":"2025-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145356831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Organotypic Airway Models Derived from Primary Human Nasal Epithelial Cells.","authors":"Jing Liu, Hsiao Hui Ong, Kun Qu, De Yun Wang","doi":"10.1007/s11882-025-01228-3","DOIUrl":"https://doi.org/10.1007/s11882-025-01228-3","url":null,"abstract":"<p><strong>Purpose of the review: </strong>The respiratory system is essential for gas exchange and immune defense but is highly susceptible to pathogens and harmful agents. Chronic rhinosinusitis, asthma, COPD, and emerging viral infections represent a global health burden. As the first line of defense, the nasal epithelium plays a central role in respiratory health. Understanding its structural and functional changes is critical for clarifying immune responses and disease mechanisms. This review summarizes recent advances in human nasal epithelial cell (hNEC) models and their applications in respiratory research.</p><p><strong>Recent findings: </strong>Submerged cultures are simple and suitable for basic assays but lack complexity, whereas air-liquid interface (ALI) cultures allow hNECs to differentiate into physiologically relevant models to preserve native epithelial signatures. It can be integrated with immune co-cultures to capture disease-specific inflammation, and are sensitive to culture expansion methods, underscoring the need for standardization. Patient-derived hNECs are increasingly used to investigate infection dynamics and provide mechanistic insight, while new apical-out organoid systems enable direct access to the epithelial surface, enhancing studies of differentiation, remodeling, and host-pathogen interactions. Nasal epithelial models, especially ALI cultures and organoids, provide powerful tools for investigating respiratory disease mechanisms and guiding therapeutic development.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":"25 1","pages":"47"},"PeriodicalIF":4.6,"publicationDate":"2025-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145350220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microneedles in Allergy Immunotherapy: the Present and Future.","authors":"Yangxue Fu, Hao Chen, Jin Liu, Qingxiu Xu, Yaqi Yang, Yin Wang, Rongfei Zhu","doi":"10.1007/s11882-025-01227-4","DOIUrl":"https://doi.org/10.1007/s11882-025-01227-4","url":null,"abstract":"<p><strong>Purpose of review: </strong>This review highlights current limitations of allergen-specific immunotherapy (AIT) methods and introduces microneedles (MNs) as an innovative transdermal platform to enhance AIT safety, efficacy, and patient adherence.</p><p><strong>Recent findings: </strong>Conventional approaches such as Subcutaneous immunotherapy (SCIT), Sublingual immunotherapy (SLIT), and Oral immunotherapy (OIT) have shown clinical effectiveness but face challenges including systemic adverse reactions, prolonged treatment durations, poor adherence. Meanwhile, Epidermal allergen-specific immunotherapy (EPIT) and other skin-targeted AIT approaches is constrained by the limited epidermal penetration of allergens. Recent preclinical studies demonstrate that MN-based transdermal immunotherapy (MN-TDIT) effectively delivers allergen directly into immune-rich dermal layers, significantly enhancing allergen-specific immune responses, inducing a regulatory T-cell response, modulating Th1/Th2 balance, and decreasing allergic inflammation in preclinical respiratory, skin, and food allergy models. MN-TDIT exhibits clear advantages over existing AIT strategies, including improved immunogenicity, fewer side effects, ease of administration, and potential for self-administration. Further research should focus on resolving formulation stability issues, optimizing controlled allergen release, and validating safety and efficacy in large-scale clinical trials, thus facilitating MNs as a transformative strategy for improving AIT outcomes.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":"25 1","pages":"46"},"PeriodicalIF":4.6,"publicationDate":"2025-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145314395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The ARIA® guidelines and the EUFOREA non-evidence-based algorithm cannot be compared and embedded in an integrated approach.","authors":"Jean Bousquet, Bernardo Sousa-Pinto, G Walter Canonica, Ludger Klimek, Boleslaw Samolinski, Torsten Zuberbier","doi":"10.1007/s11882-025-01223-8","DOIUrl":"10.1007/s11882-025-01223-8","url":null,"abstract":"","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":"25 1","pages":"45"},"PeriodicalIF":4.6,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12513963/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145276687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Using Biologics in the Prevention of Anaphylaxis.","authors":"Daniel Song, Amika K Sood, Stephen A Schworer, Onyinye I Iweala, Mildred Kwan","doi":"10.1007/s11882-025-01224-7","DOIUrl":"https://doi.org/10.1007/s11882-025-01224-7","url":null,"abstract":"<p><strong>Purpose of review: </strong>Until recently, the management of anaphylaxis has been dependent on the avoidance of known triggers combined with the emergent treatment of immediate and, possibly, fatal hypersensitivity reactions. The approval of omalizumab for the prevention of food-induced anaphylaxis heralds a new era for the use of biologics to curtail anaphylactic reactions in susceptible individuals.</p><p><strong>Recent findings: </strong>As more knowledge is gleaned about the immunologic mechanisms of anaphylaxis, the application of biologics for prophylaxis of anaphylaxis has accelerated. While omalizumab is currently the only approved biologic for averting anaphylaxis, data is accumulating for the use of other biologics as well. These include monoclonal antibodies that target IgE, mast cell receptors, cytokines, and alarmins.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":"25 1","pages":"44"},"PeriodicalIF":4.6,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145253654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phenotypic Features of Central Compartment Atopic Disease Compared with Other Types of Chronic Rhinosinusitis: A Systematic Review.","authors":"Julissa Vizcarra-Melgar, Ramón Moreno-Luna, Daniel Martín-Jiménez, Concepción Gago-Torres, Carmen Palma-Martínez, Miriam González-García, Lucía Prieto-Sánchez De Puerta, Meritxell Clarí-Comes, Jaime González-García, Pedro Infante-Cossío, Serafín Sánchez-Gómez","doi":"10.1007/s11882-025-01225-6","DOIUrl":"https://doi.org/10.1007/s11882-025-01225-6","url":null,"abstract":"<p><strong>Purpose of review: </strong>Central Compartment Atopic Disease (CCAD) is an emerging phenotype of chronic rhinosinusitis. The absence of a standardized diagnostic framework and the presence of heterogeneous reported characteristics underscore the importance of consolidating current knowledge on CCAD. This review aims to enhance understanding of the CCAD phenotype by focusing on its clinical and radiologic features, its association with inhalant allergies, and its therapeutic implications in comparison with other chronic rhinosinusitis phenotypes.</p><p><strong>Methods: </strong>A systematic review was conducted through searches in five databases from 2017 to June 2025 following SWiM guidelines. The methodological quality and risk of bias of the included studies were evaluated using the Oxford Centre for Evidence-Based Medicine criteria. Data were analyzed using descriptive and qualitative synthesis.</p><p><strong>Results: </strong>Seventeen studies were included for qualitative synthesis. CCAD diagnosis relied mainly on endoscopic and radiologic findings, often supported by allergy testing. Most patients showed lower rates of asthma, with variable allergic sensitization rates across populations and elevated blood and tissue eosinophils. Compared to other phenotypes, CCAD showed milder disease and favorable outcomes after endoscopic sinus surgery.</p><p><strong>Conclusion: </strong>CCAD presents unique clinical and immunologic features that differ from other chronic rhinosinusitis subtypes. Standardized diagnostic criteria are needed to improve recognition and guide tailored management strategies.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":"25 1","pages":"43"},"PeriodicalIF":4.6,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145240347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sarcoidosis in the Genomic Era: From Genetic Drivers to Tailored Therapies.","authors":"Natalia V Rivera, Dominique Israël-Biet","doi":"10.1007/s11882-025-01222-9","DOIUrl":"10.1007/s11882-025-01222-9","url":null,"abstract":"<p><strong>Purpose of review: </strong>This review aims to synthesize existing literature on the genetics of sarcoidosis, including the genetic architectures associated with various clinical phenotypes, as well as current treatment options. It will also examine studies on phenotyping and endophenotyping sarcoidosis, along with offering new perspectives into pharmacogenetics and pharmacogenomics. The latter remains largely unexplored, which could potentially lead to new opportunities and further the goals of precision medicine.</p><p><strong>Recent findings: </strong>Genetics and genomics have provided new insights into the study of sarcoidosis. According to current literature, there are variations in the genetic structure of sarcoidosis when categorized by phenotypic definitions. A common element among these findings is the HLA-DRB1 gene, which is associated with many autoimmune diseases. Genetic analysis is a valuable tool for identifying patient groups based on their genetic profiles, offering an opportunity to classify patients for targeted treatment approaches. Genetics can provide valuable insights that, when combined with other omics disciplines, can aid in diagnosing and managing sarcoidosis and help discover new disease biomarkers. Genetics improve the detection of sarcoidosis endophenotypes, and the combination of pharmacogenetics and pharmacogenomics will support the use of appropriate treatments and help eliminate unnecessary therapies in patients with specific genetic susceptibility.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":"25 1","pages":"42"},"PeriodicalIF":4.6,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12484292/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145201624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Detection of Anaphylaxis Through the Cutaneous Barrier.","authors":"Anjali Sundar, Marc S McMorris, Charles F Schuler","doi":"10.1007/s11882-025-01218-5","DOIUrl":"10.1007/s11882-025-01218-5","url":null,"abstract":"<p><strong>Purpose of review: </strong>The capacity to rapidly and objectively detect impending anaphylaxis is a crucial unmet need in food allergy, as clinical impression remains the only means of anaphylaxis diagnosis. Changes in the cutaneous barrier during an allergic reaction might offer an objective, rapid, and accessible anaphylaxis detection method.</p><p><strong>Recent findings: </strong>Changes in cutaneous temperature and skin permeability might serve as markers of anaphylaxis. Existing methods around facial thermography, cutaneous blood flow measurements, electrical impedance spectroscopy, and transepidermal water loss (TEWL) offer varied data as possible food anaphylaxis biomarkers. Further data is needed to validate these and other methods as a means to non-invasively detect anaphylaxis. This review describes key advances in anaphylaxis detection through the cutaneous barrier, most notably around skin barrier function in the context of atopic dermatitis and food allergy.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":"25 1","pages":"41"},"PeriodicalIF":4.6,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12477081/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145187632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"4-Week Maintenance ICS-Formoterol versus ICS in Adults Newly Diagnosed Mild Asthma: Effects on Symptoms, Lung Function, and Inflammation.","authors":"Yan Zhou, Xue Zhang, Zichong Xu, Jinwen Wang, Yilin Pan, Yingying Zhang, Xue Tian, Yuning Huang, Chengjian Lv, Qi Zheng, Wuping Bao, Min Zhang","doi":"10.1007/s11882-025-01217-6","DOIUrl":"10.1007/s11882-025-01217-6","url":null,"abstract":"<p><strong>Purpose of review: </strong>This study aimed to determine whether patients with newly diagnosed mild asthma benefit more from initiating treatment with maintenance inhaled corticosteroids (ICS) plus formoterol versus ICS alone. We compared the effects of these two 4-week maintenance strategies on asthma control, lung function, and airway inflammation.</p><p><strong>Recent findings: </strong>Recent evidence supports the effectiveness of as-needed ICS-formoterol in mild asthma management. However, data on initial short-term maintenance strategies remain limited. Most studies focus on long-term outcomes or symptom-driven therapy, with little insight into the early phase and its impact on inflammation and lung function. Notably, GINA 2024 emphasizes that \"mild asthma\" is a retrospective label and may not reliably guide the selection of the appropriate initial treatment step. Even in so-called mild asthma, severe outcomes may occur, highlighting the need for early, objective assessment to guide treatment decisions. In this retrospective analysis of two prospective studies including 128 patients with newly diagnosed mild asthma, both the ICS-formoterol and ICS groups showed improvements in asthma control, lung function, and airway inflammation. However, the ICS-formoterol group achieved significantly greater improvements in Asthma Control Test scores, Asthma Control Questionnaire scores, large airway function (FEV₁, FEV₁/FVC), small airway function, and eosinophil reduction, particularly in patients with baseline small airway dysfunction. FEV₁ reversibility in baseline bronchodilation test was positively correlated with improvements in FEV₁, FEV₁/FVC, and eosinophil count reduction in the ICS-formoterol group. These findings support 4-week ICS-formoterol maintenance therapy as an effective initial strategy in mild asthma, with reassessment guiding longer-term management.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":"25 1","pages":"40"},"PeriodicalIF":4.6,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145126656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}